Stock Track | Haixi Pharma Soars 14.56% Intraday on First Broker Coverage and Pipeline Optimism

Stock Track04-27

Haixi Pharma's stock surged 14.56% during intraday trading on Monday, marking a significant upward movement.

The rally was primarily driven by Shenwan Hongyuan's first-ever coverage of the company, assigning a Buy rating with a target price of HK$298.28. The research report highlighted the company's solid financial performance, with its generic drug business achieving profitability for five consecutive years, supported by strong revenue and net profit growth.

Investor optimism was further bolstered by progress in Haixi Pharma's innovative drug pipeline. The lead candidate C019199 for osteosarcoma is expected to enter Phase III clinical trials soon, while HXP056, a next-generation oral treatment for fundus diseases, has shown favorable early data and is advancing in Phase II trials, with potential blockbuster prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120458534?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-27 09:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120458534","market":"sg","top_or_hot":-1,"title":"Stock Track | Haixi Pharma Soars 14.56% Intraday on First Broker Coverage and Pipeline Optimism","media":"Stock Track","content":"<p>Haixi Pharma's stock surged 14.56% during intraday trading on Monday, marking a significant upward movement.</p><p>The rally was primarily driven by Shenwan Hongyuan's first-ever coverage of the company, assigning a Buy rating with a target price of HK$298.28. The research report highlighted the company's solid financial performance, with its generic drug business achieving profitability for five consecutive years, supported by strong revenue and net profit growth.</p><p>Investor optimism was further bolstered by progress in Haixi Pharma's innovative drug pipeline. The lead candidate C019199 for osteosarcoma is expected to enter Phase III clinical trials soon, while HXP056, a next-generation oral treatment for fundus diseases, has shown favorable early data and is advancing in Phase II trials, with potential blockbuster prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Haixi Pharma Soars 14.56% Intraday on First Broker Coverage and Pipeline Optimism</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Haixi Pharma Soars 14.56% Intraday on First Broker Coverage and Pipeline Optimism\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-27 09:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Haixi Pharma's stock surged 14.56% during intraday trading on Monday, marking a significant upward movement.</p><p>The rally was primarily driven by Shenwan Hongyuan's first-ever coverage of the company, assigning a Buy rating with a target price of HK$298.28. The research report highlighted the company's solid financial performance, with its generic drug business achieving profitability for five consecutive years, supported by strong revenue and net profit growth.</p><p>Investor optimism was further bolstered by progress in Haixi Pharma's innovative drug pipeline. The lead candidate C019199 for osteosarcoma is expected to enter Phase III clinical trials soon, while HXP056, a next-generation oral treatment for fundus diseases, has shown favorable early data and is advancing in Phase II trials, with potential blockbuster prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02637","symbol_name":"海西新药","start_time":0,"source_url":"","article_id":"1120458534","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120458534","pubTimestamp":1777254687,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Haixi Pharma's stock surged 14.56% during intraday trading on Monday, marking a significant upward movement.The rally was primarily driven by Shenwan Hongyuan's first-ever coverage of the company,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02637":"海西新药"},"translate_title":"个股赛道|首家券商覆盖叠加管线乐观海西药业盘中大涨14.56%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02637":1},"content_text":"Haixi Pharma's stock surged 14.56% during intraday trading on Monday, marking a significant upward movement.The rally was primarily driven by Shenwan Hongyuan's first-ever coverage of the company, assigning a Buy rating with a target price of HK$298.28. The research report highlighted the company's solid financial performance, with its generic drug business achieving profitability for five consecutive years, supported by strong revenue and net profit growth.Investor optimism was further bolstered by progress in Haixi Pharma's innovative drug pipeline. The lead candidate C019199 for osteosarcoma is expected to enter Phase III clinical trials soon, while HXP056, a next-generation oral treatment for fundus diseases, has shown favorable early data and is advancing in Phase II trials, with potential blockbuster prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120458534","isCrawlerRequest":true}